A Wall Street analyst issued contrasting ratings on Tuesday for two major diagnostic testing companies, upgrading shares of ...

Citi upgraded Charles River Laboratories (NYSE:CRL) and LabCorp (NYSE:LH) while downgrading Quest Diagnostics (NYSE:DGX), ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

After hours: March 14 at 7:56:51 PM EDT Loading Chart for DGX ...

Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic ...

Competitive Landscape: Quest Diagnostics faces intense competition, primarily from LabCorp, other commercial laboratories and hospitals. While pricing is an important factor in choosing a testing ...

据贝哲斯咨询发布的2024版健康测试市场分析报告，全球和中国健康测试市场规模在2023年分别达到 亿元（人民币）与 亿元。报告结合健康测试行业发展环境和市场动态，对未来几年内健康测试市场做出了合理预测。报告预计至2029年全球健康测试市场规模将会达到 ...

The independent laboratory company has entered an agreement to acquire BioReference Health's oncology diagnostic services.

Fresenius Medical (FMS) and Quest Diagnostics (DGX) announced that, under terms of a definitive acquisition agreement, Quest will acquire select assets of FME’s wholly owned Spectra Laboratories ...

NEW YORK – Kidney dialysis firm Fresenius Medical Care said Monday that it is selling select laboratory assets to Quest Diagnostics. Quest is acquiring select assets of Fresenius' Spectra Laboratories ...